DK0623112T3 - 4-phenyl-3-(heteroarylureido)-1,2-dihydro-2-oxoquinolinderivater som antihypercholesterolæmiske og antiatherosclerotiske mi - Google Patents

4-phenyl-3-(heteroarylureido)-1,2-dihydro-2-oxoquinolinderivater som antihypercholesterolæmiske og antiatherosclerotiske mi

Info

Publication number
DK0623112T3
DK0623112T3 DK93901257T DK93901257T DK0623112T3 DK 0623112 T3 DK0623112 T3 DK 0623112T3 DK 93901257 T DK93901257 T DK 93901257T DK 93901257 T DK93901257 T DK 93901257T DK 0623112 T3 DK0623112 T3 DK 0623112T3
Authority
DK
Denmark
Prior art keywords
formula
nitrogen
group
compounds
optionally substituted
Prior art date
Application number
DK93901257T
Other languages
Danish (da)
English (en)
Inventor
Ernest S Hamanaka
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0623112T3 publication Critical patent/DK0623112T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK93901257T 1992-01-23 1992-12-21 4-phenyl-3-(heteroarylureido)-1,2-dihydro-2-oxoquinolinderivater som antihypercholesterolæmiske og antiatherosclerotiske mi DK0623112T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82463992A 1992-01-23 1992-01-23
PCT/US1992/010886 WO1993015058A1 (fr) 1992-01-23 1992-12-21 Derives de 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline utilises comme agents antihypercholesterolemie et antiatherosclerose

Publications (1)

Publication Number Publication Date
DK0623112T3 true DK0623112T3 (da) 1999-08-30

Family

ID=25241935

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93901257T DK0623112T3 (da) 1992-01-23 1992-12-21 4-phenyl-3-(heteroarylureido)-1,2-dihydro-2-oxoquinolinderivater som antihypercholesterolæmiske og antiatherosclerotiske mi

Country Status (16)

Country Link
EP (1) EP0623112B1 (fr)
JP (1) JP2668163B2 (fr)
KR (1) KR950700284A (fr)
AT (1) ATE175196T1 (fr)
AU (1) AU3323393A (fr)
CA (1) CA2128093C (fr)
DE (1) DE69228069T2 (fr)
DK (1) DK0623112T3 (fr)
ES (1) ES2125325T3 (fr)
FI (2) FI930264A7 (fr)
HU (1) HUT63625A (fr)
IL (1) IL104420A0 (fr)
MX (1) MX9300361A (fr)
NO (1) NO942757D0 (fr)
WO (1) WO1993015058A1 (fr)
ZA (1) ZA93482B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133326A (en) * 1994-08-31 2000-10-17 Pfizer Inc Compositions and methods for decreasing sebum production
WO1999043659A1 (fr) * 1998-02-25 1999-09-02 Sumitomo Pharmaceuticals Co., Ltd. Derives de pyridone et leur procede de fabrication
US6452008B2 (en) 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
GEP20043286B (en) 2000-02-02 2004-07-26 Warner Lambert Co Dual Inhibitors of Cholesteryl Ester and Wax Ester Synthesis for Sebaceous Gland Disorders
NZ544472A (en) 2003-07-03 2009-04-30 Myriad Genetics Inc Compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
EP1771456A2 (fr) * 2004-07-30 2007-04-11 Palumed SA Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
FR2874922A1 (fr) * 2004-07-30 2006-03-10 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (fr) 2005-01-03 2006-07-13 Myriad Genetics Inc. Composes et utilisation therapeutique associee
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE892088L (en) * 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use
WO1991004027A1 (fr) * 1989-09-15 1991-04-04 Pfizer Inc. Nouveaux derives de n-aryle de n-heteroarylamide et d'uree en tant qu'inhibiteurs d'acyl coenzyme a: cholesterol acyl transferase
TW205037B (fr) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
US5278186A (en) * 1990-02-10 1994-01-11 Takeda Chemical Industries, Ltd. Chromene derivatives, their production and use
WO1992019614A1 (fr) * 1991-04-26 1992-11-12 Pfizer Inc. Derives de 4-aryle-3-(heteroarylureido)quinoline

Also Published As

Publication number Publication date
JPH07503712A (ja) 1995-04-20
MX9300361A (es) 1994-06-30
NO942757L (no) 1994-07-22
AU3323393A (en) 1993-09-01
CA2128093A1 (fr) 1993-08-05
HU9300197D0 (en) 1993-04-28
WO1993015058A1 (fr) 1993-08-05
KR950700284A (ko) 1995-01-16
ES2125325T3 (es) 1999-03-01
ZA93482B (en) 1994-07-22
EP0623112A1 (fr) 1994-11-09
IL104420A0 (en) 1993-05-13
DE69228069D1 (de) 1999-02-11
ATE175196T1 (de) 1999-01-15
DE69228069T2 (de) 1999-05-20
FI20010074A7 (fi) 2001-01-12
JP2668163B2 (ja) 1997-10-27
FI930264A0 (fi) 1993-01-22
EP0623112B1 (fr) 1998-12-30
CA2128093C (fr) 1998-02-03
NO942757D0 (no) 1994-07-22
HUT63625A (en) 1993-09-28
FI930264A7 (fi) 1993-07-24

Similar Documents

Publication Publication Date Title
NO20013379L (no) 4-okso-1,4-dihydro-3-kinolinkarboksamider som antivirusmidler
DK0623112T3 (da) 4-phenyl-3-(heteroarylureido)-1,2-dihydro-2-oxoquinolinderivater som antihypercholesterolæmiske og antiatherosclerotiske mi
FI943561A0 (fi) Uudet ainekoostumukset
DK283589D0 (da) 1-indolylalkyl-4-(substitueret pyridinyl)-piperaziner
DK1026147T3 (da) Forbindelser, der er anvendelige som mellemprodukter i fremstillingen af piperidinderivater
YU17092A (sh) Derivati 2,4-diaminohinazolina
FI946083A0 (fi) Antianginaaliset purinonit
DK345989A (da) Quinolinderivater
TW256832B (fr)
DK1113011T3 (da) Aminotetrazol-derivater, der er anvendelige som nitrogenoxidsynthaseinhibitorer
DK0600950T3 (da) Tetrazolamider som inhibitorer af ACAT
DE69314929D1 (de) Benzolderivate
ES2077697T3 (es) Derivados de 1-fenoxicarbonil-2-pirrolidinona y agentes nootropicos.
YU90192A (sh) LANOSTA-7,9-DIEN-3β, 32-DIOL I POSTUPAK ZA NJEGOVO DOBIJANJE,9-DIEN-3BETA, 32-DIOL I POSTUPAK ZA NJEGOVU SINTEZU